The Cooper Companies, IncNasdaq: COO
Health Care · Health Care Supplies
$62.34
-0.89%
Vol: 1.3M
Research Digest
Friday, May 1, 2026
Q1 raised FY guidance amid strong revenue; Jana Partners restructure pressure active
Cooper Companies reported strong Q1 with $1.02B revenue and raised full-year guidance. Analyst consensus Buy with $90.18 PT (+40% upside). Jana Partners pushing strategic restructuring to potentially break up company, citing underperformance. CooperVision and CooperSurgical positioned for continued market share gains in contact lenses and fertility/women's health. Stock fell 9.9% on recent weakness amid activist pressure and strategic review. FY2025: $4.09B revenue (+5.06% YoY). Bear case: activist campaign may distract management.
Previous Market Intelligence
13 daysApr 30Cooper Companies reports strong Q1 results with strategic review underwayMixed▶
Cooper Companies reported robust Q1 2026 results with record $1.065B revenue (+4.6% YoY), raising full-year guidance amid ongoing strategic review to enhance shareholder value. Jana Partners has been pushing for a breakup of the company. Q1 showed strong performance across both CooperVision and CooperSurgical business units. Stock fell -8.39% over the past week and -10.03% for the month, trading at $63.09. Citi lowered price target to $80 from $87, while 11 analysts average a Buy rating with $90.18 target (+39.99% upside). Medical device sector headwinds persist.
Apr 16Cooper Companies raised full-year 2026 EPS guidance to $4.62 midpoint after Q1 earnings beatPositive▶
Cooper Companies reported strong Q1 2026 results with $1.02 billion revenue, 3% organic revenue growth YoY, and adjusted EPS of $1.10 (up 20% YoY), leading to raised full-year 2026 guidance of $4.62 adjusted EPS at midpoint. Shareholders approved all board nominees and KPMG as auditor on April 7. The company is focusing on sustainability with its MADE BETTER Promise while addressing competitive challenges.
Apr 15Cooper Companies raised FY2026 adjusted EPS guidance to $4.62 midpoint ahead of consensus; activist Jana building position.Positive▶
Cooper Companies opened FY2026 with 3% organic revenue growth YoY and adjusted EPS of $1.10 (+20% YoY), raising full-year guidance to $4.62 EPS midpoint ahead of FactSet consensus of $4.52. Activist investor Jana Partners building top portfolio position and pushing for strategic alternatives. Consensus from 11 analysts: Buy with $89.64 PT.
Apr 14Cooper Companies stockholders approve 2026 proposals; Citi lowers price target to $80; MADE BETTER sustainability initiative launched.Positive▶
Cooper Companies held stockholder meeting April 7 where shareholders elected all nine directors and ratified KPMG as auditor. Citi lowered price target from $87 to $80. CooperVision introduced MADE BETTER Promise sustainability platform. FY 2026 guidance calls for 4.5-5.5% organic growth. Analyst consensus Buy with $89.64 average target.
Apr 13Cooper Companies shareholders approve 2026 proposals while new MADE BETTER sustainability platform launches.Positive▶
Cooper Companies held its annual shareholders meeting on April 7 where stockholders elected all nine director nominees and ratified KPMG. CooperVision launched the MADE BETTER Promise sustainability platform beginning with MyDay daily disposable lenses. Updated fiscal 2026 guidance calls for 4.5% to 5.5% organic growth.
Apr 10Cooper Companies shareholders approve all governance proposals; MyDAY supply constraints resolved with 30+ new contracts.Neutral▶
Cooper Companies held April 7 shareholder meeting with full approval of governance proposals. Company resolved manufacturing constraints for premium MyDAY lens and accelerating global rollout with 30+ new private label contracts. Q1 2026 revenue $1.02B with raised full-year guidance. Analyst consensus Moderate Buy from 17 analysts with $90.79 target.
Apr 9Cooper Companies raises FY2026 guidance on strong Q1, manages debt maturity extensionPositive▶
Cooper Companies reported Q1 2026 revenue of $1.02 billion with net income of $130.8 million. Company raised FY2026 guidance to $4.58-$4.66 EPS. CooperVision revenue expected $2.9-$2.93 billion (+4.5-5.5% organic) and CooperSurgical $1.4-$1.41 billion (+4-5% organic). Extended $950 million of $1.5 billion term loan maturing December 2026 for five years to February 2031; remaining $550 million to be repaid from strong free cash flow. Repurchased $92.5 million shares in Q1. Shareholders elected all directors and approved executive compensation. Activist investor Jana Partners announced top portfolio position in Cooper and plans to push for strategic alternatives. Stock at $83.99 with 6.75% upside to $89.64 price target from 11 analysts with Buy rating.
Apr 8Cooper Companies initiated a formal strategic review to identify opportunities for enhancing shareholder value, with activist investor Jana announcing a top position in the company.Positive▶
Cooper Companies announced a strategic review and faces activist investor interest from Jana Partners, which plans to push for strategic alternatives including potential combinations for its contact lens unit. The company raised price targets at Needham to $101 from $99. Analyst consensus remains Buy with an average 12-month target of $89.64. Cooper operates CooperVision (contact lens) and CooperSurgical (medical devices), controlling roughly one-fourth of the US contact lens market and 17% of the US IUD market.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Cooper Q1 FY2026 strong; raised full-year guidance.Positive▶
Cooper Companies reported Q1 FY2026 revenue of $1.02B with strong performance. Raised full-year FY2026 guidance to $4,299-$4,338M revenue and non-GAAP EPS $4.45-$4.60. Needham PT $101.
Apr 3Cooper Companies raises full-year 2026 guidance after strong Q1 results; free cash flow increased to $600-625M.Positive▶
Cooper Companies reported strong Q1 2026 results with $1.02 billion in revenue. Non-GAAP EPS grew 20% to $1.10 with operating margins of 26.9%. The company raised Non-GAAP EPS guidance to $4.58-$4.66 and increased free cash flow guidance to $600-$625 million. The company completed $92.5M in share repurchases.
Apr 2Cooper Companies launches formal strategic review to simplify business; CooperVision gains market share 18th consecutive year.Positive▶
Cooper Companies initiated Board strategic review exploring partnerships, JVs, divestitures, mergers to unlock shareholder value and simplify structure. CooperVision gained market share 18 consecutive years; operating margins improved to 26.9% with structural cost reductions. Colleen Jay appointed Chair effective Jan 2, 2026. FY2025: revenue $4.092B (+5% reported, +4% organic). Needham raised PT to $101 (from $99) March 6. 11 analysts avg Buy, PT $89.64.
Apr 1Cooper Companies initiates strategic review following activist investor Jana Partners stake; stock up 11.7%.Positive▶
Cooper Companies announced formal strategic review, sending shares up 11.7%. Activist investor Jana Partners disclosed a top portfolio position and plans to push for strategic alternatives. Fiscal 2026 guidance of $4,299-$4,338M revenue and $4.45-$4.60 non-GAAP EPS.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WSTWEST | $300.73 | +1.05% | +15.9% | 31.1x | 1.15 | $21.0B |
| ALGNALIGN | $178.92 | +1.65% | +2.4% | 14.2x | 1.81 | $12.6B |
| COOCOOPER | $62.34 | -0.89% | -10.5% | 12.5x | 1.07 | $12.3B |
| LLYELI | $964.50 | +3.20% | +0.8% | 22.2x | 0.50 | $834.9B |
| JNJJOHNSON | $227.78 | -0.90% | -4.6% | 18.1x | 0.33 | $553.3B |
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.